AbbVie Humira Patent Thicket Delays US Biosimilars Until 2023 Despite 2016 Patent Expiration and European Competition

AbbVie reached settlement agreements with eight biosimilar manufacturers that allowed immediate biosimilar competition in Europe starting October 16, 2018, but delayed all US market entry until 2023—seven years after Humira’s original patent expired in December 2016. The settlements ended …